Abstract:Importance: Mental health disorders are prevalent yet undertreated health conditions in the US. Given perceptions about the potential effect of cannabis on individuals with mental health disorders, there is a need to understand the association of cannabis laws with psychotropic use. Objective: To investigate the association of medical and recreational cannabis laws and dispensary openings with the dispensing of psychotropic medications used to treat mental health disorders in the US. Design, setting, and participants: This cross-sectional study of 10 013 948 commercially insured patients used a synthetic control method to examine the association of cannabis policies with prescribing. Data on all patients dispensed prescriptions for each of the 5 classes of psychotropic medications from January 1, 2007, to December 31, 2020, were extracted from Optum's deidentified Clinformatics Data Mart Database. Statistical analysis was performed from September 2022 to November 2023. Exposures: The 4 exposure variables measured were whether medical or recreational cannabis laws were in effect and whether medical or recreational cannabis dispensaries were open in each state and calendar quarter. Main outcome and measures: One measure of the extensive margins of dispensing and 2 measures of the intensive margins of dispensing were constructed for 5 medication classes (benzodiazepines, antidepressants, antipsychotics, barbiturates, and sleep medications). Results: The primary sample (the benzodiazepine sample) included 3 848 721 patients (mean [SD] age, 46.1 [11.4] years; 65.4% women; 53.7% aged 35-54 years). Medical cannabis laws were associated with a 12.4% reduction in the benzodiazepine fill rate (average treatment effect on the treated [ATT], -27.4; 95% CI, -14.7 to 12.0; P = .001), recreational cannabis laws were associated with a 15.2% reduction in the fill rate (ATT, -32.5; 95% CI, -24.4 to 20.1; P = .02), and medical cannabis laws were associated with a 1.3% reduction in the mean number of benzodiazepine fills per patient (ATT, -0.02; 95% CI, -0.02 to 0.02; P = .04). Medical dispensaries were associated with a 3.9% reduction in mean days' supply per benzodiazepine fill (ATT, -1.7; 95% CI, -0.8 to 0.6; P = .001), while recreational dispensaries were associated with a 6.2% reduction (ATT, -2.4; 95% CI, -1.0 to 0.9; P < .001). Medical cannabis laws were associated with a 3.8% increase in antidepressant fills (ATT, 27.2; 95% CI, -33.5 to 26.9; P = .048), and medical dispensaries were associated with an 8.8% increase (ATT, 50.7; 95% CI, -32.3 to 28.4; P = .004). The mean number of antipsychotic medication fills per patient increased by 2.5% (ATT, 0.06; 95% CI, -0.04 to 0.05; P = .02) after medical cannabis laws and by 2.5% (ATT, 0.06; 95% CI, -0.04 to 0.04; P = .02) after medical dispensary openings. Findings for the other drug classes showed substantial heterogeneity by state and direction of association. Conclusions and relevance: This cross-sectional study of commercially insured patients suggests that there may have been meaningful heterogeneous associations between cannabis policy and state and between cannabis policy and drug class (eg, decreases in dispensing of benzodiazepines but increases in dispensing of antidepressants and antipsychotics). This finding suggests additional clinical research is needed to understand the association between cannabis use and mental health. The results have implications for patient substance use and mental health-related outcomes.

The addition of cannabis to prescription drug monitoring programs and medication fills in Medicaid

Medical Cannabis Legalization and Opioid Prescriptions: Evidence on US Medicaid Enrollees During 1993–2014

Association between prescription drug monitoring programs use mandates and prescription stimulants received by Medicaid enrollees

The Combined Relationship of Prescription Drug Monitoring Program Enactment and Medical Cannabis Laws with Chronic Pain-Related Healthcare Visits

Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders

Outpatient Prescription Cannabinoid Utilisation in the USA: a Population-Based Study.

Pronounced State-Level Disparities in Prescription of Cannabinoids to Medicaid Patients

Medical Marijuana Had No Impact on Amphetamine Prescribing in Medicaid

Recreational Marijuana Legalization and Prescription Opioids Received by Medicaid Enrollees.

Measuring the Impact of Medical Cannabis Law Adoption on Employer-Sponsored Health Insurance Costs: A Difference-in-Difference Analysis, 2003-2022

Impact of Recreational Cannabis Legalization on Opioid Prescribing and Opioid-Related Hospital Visits in Colorado: an Observational Study

Mandatory Use of Prescription Drug Monitoring Program and Benzodiazepine Prescribing among U.S. Medicaid Enrollees.

The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare

Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada

Trends in Medical Encounters Involving Cannabis-Related Disorders Among US Medicare Beneficiaries, 2017–2022

Shared Control Individuals in Health Policy Evaluations with Application to Medical Cannabis Laws

The Effect of Prescription Drug Monitoring Programs on Opioid Prescriptions and Heroin Crime Rates

Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004-2019

Cannabis Use in Parkinson's Disease: Patient Access to Medical Cannabis and Physician Perspective on Product Safety

Using real world evidence to optimize care: the case of medical cannabis

Examining the effect of prescription drug monitoring program integration and mandatory use policies on the distribution of methadone and buprenorphine for opioid use disorder, United States, 2009-2021